|
|
| Blue
Bell, PA – June 2, 2008 – |
|
VGX Pharmaceuticals, Inc. (VGX) announced today the
promotion of Mr. Anthony K. Kim to Senior Director, Strategic Operations.
Mr. Kim has been serving as the Director of Investor Relations. Since
joining VGX in 2005, Mr. Kim has been responsible for Investor Relations,
addressing the needs of our diverse group of investors for both VGX and
its affiliate, VGX International, a publicly-traded biopharmaceutical
company based in Korea. Mr. Kim has also played an important role in various
corporate development operations including management of corporate strategies
at VGX International.
“Anthony has been providing invaluable services to many aspects
of our business,” said Dr. J. Joseph Kim, CEO and President. “This
promotion recognizes the important role he has played in our Company’s
growth and I expect his role and contributions to continue to grow.”
Anthony Kim has over 10 years of experience in the securities and banking
industry. Prior to joining the Company, he led a financials services company
for which he assisted his clients in raising money from high net-worth
individuals and financial institutions. Mr. Kim holds a Bachelor's Degree
in Economics from the University of Washington.
Cautionary Factors That May Affect Future
Results - Materials in this Web site contain information
that includes or is based upon forward-looking statements within the
meaning of the Securities Litigation Reform Act of 1995. Forward-looking
statements relate to expectations or forecasts of future events. You
can identify these statements by the fact that they do not relate
strictly to historical or current facts. They use words such as "anticipate,"
"estimate," "expect," "project," "intend,"
"plan," "believe," and other words and terms of
similar meaning in connection with a discussion of potential future
events, circumstances or future operating or financial performance.
In particular, these include statements relating to future actions,
prospective products or product approvals, future performance or results
of current and anticipated products, sales efforts, expenses, the
outcome of contingencies such as legal proceedings, and financial
results. Any or all of our forward-looking statements here or in other
publications may turn out to be wrong. They can be affected by inaccurate
assumptions or by known or unknown risks and uncertainties. Many such
factors will be important in determining our actual future results.
Consequently, no forward-looking statement can be guaranteed, and
forward-looking statements may be adversely affected by factors, including
general market conditions, competitive product development, product
availability, current and future branded and generic competition,
federal and state regulations and legislation, manufacturing issues,
timing of the elimination of trade buying, patent positions, litigations
and investigations. Our actual results may vary materially, and there
are no guarantees about the performance or valuation of VGX stock.
It is also important to read the disclosure notice contained in many
of the individual VGX documents available on this Web site as many
contain important information on such cautionary factors as of the
date of the individual document. We undertake no obligation to correct
or update any forward-looking statements, whether as a result of new
information, future events or otherwise. You are advised, however,
to consult any further disclosures we make on related subjects in
our reports. |
About VGX
Pharmaceuticals
VGX Pharmaceuticals is a biopharmaceutical company with small molecule
and biologic product candidates for the treatment of infectious diseases,
cancer, and inflammatory diseases. The Company's clinical development
programs include PICTOVIR™ for HIV infection, which is in Phase
II clinical trials, PENNVAX™-B for HIV infection, which is in 2
separate Phase I clinical trials, and VGX-1027 for inflammatory diseases,
which is in Phase I clinical trials. In addition, the Company has filed
INDs for VGX-3100, a DNA therapeutic vaccine for cervical cancer; VGX-3200,
a novel DNA therapy that utilizes GHRH for the treatment of cancer cachexia
and anemia; and VGX-3400, a DNA preventative vaccine for avian influenza.
VGX has established a vertically-integrated DNA Vaccines and Therapies
Platform with extensive capabilities including SynCon™ DNA-based
product candidates, the CELLECTRA® delivery device, and
efficient cGMP plasmid manufacturing facilities. The cGMP facilities are
used for VGX’s own product supplies and for contract manufacturing.
Vertical control over key aspects of product development has enabled the
Company to consistently develop multiple product candidates, from bench-to-IND
filing, within 1 year. The product candidates and technology programs
are protected by the Company's extensive global intellectual property
portfolio. More information about VGX can be found at www.vgxp.com.
Company Contact:
Kevin W. Rassas
Senior Vice President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com
|
